|
|
楼主 |
发表于 2015-7-8 13:43:18
|
显示全部楼层
来自： 美国
1. https://clinicaltrials.gov/ct2/s ... 378+ros1&rank=4
"Experimental: LDK378
25 NSCLC patients.Patient's tumor must have ALK or ROS1 gene rearrangement.
Drug: LDK378
LDK378 will be dosed as 750 mg once daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take LDK378 exactly as prescribed."
广州这个 LDK378 药试, 设计招收 ALK 阳性, 或 ROS1 阳性, 非小肺癌病人, 共 25 人. 具体有多少 ROS1 病人, 我们得等结果出来才能知晓;
2. ROS1融合患者在克耐药后有没有可能出现RET融合？
理论上, 有可能, 但可能性微小得很. 目前为止, ALK 和 EGFR 双阳性的病人, 广州吴医生有正式报道过, 美国这边好似还没有记载. ROS1 + RET 双阳性??? I don't know.
3. I don't have patient evidence to argue for AP26113 on ROS1 patients. My reference was from ASCO 2013, Abstract 8031, report by R Camidge, L Bazhenova, R Salgia, GJ Weiss, CJ Langer, AT Shaw, NI Narasimhan, DJ Dorer, VM Rivera, J Zhang, T Clackson, FG Haluska, SN Gettinger.
- in cell culture, AP26113 IC50 for CD74-ROS1 was, 18 nM, on par with EML4-ALK, 17 nM; for EGFR T790M, 282 nM and 694 nM. Extrapolating from these numbers, AP26113 has much better chance to be effective on ROS1 NSCLC, than on EGFR T790M mutant NSCLC
- in 2013, the 5 cohorts design for AP26113 included cohort 4 - "other cancers with AP26113 targets, eg ALK, ROS1, and others". But later I think they dropped that cohort as well as the EGFR T790M cohort (#3).
https://clinicaltrials.gov/ct2/s ... =ap26113&rank=1
The current AP26113 phase 2 has only 2 cohorts, both ALK+ NSCLC, only difference is dosage, cohort 1 is on 90 mg, cohort 2 is 180 mg.
I am in phase 1, and am taking 240 mg after doctor approval (for exception).
Maybe, let me ask you, when you say ROS1+ patients in China tried AP26113, almost no one had success. How many patients? How big is your sample size?
<google translation>
我没有 'bing'ren 的证据来主张AP26113的ROS1患者。我参照的是来自ASCO 2013，8031摘要，由R Camidge，L巴热诺娃，R Salgia，GJ魏斯，CJ兰格，肖倪纳拉辛汉，DJ Dorer，VM里维拉，J张，T Clackson，FG Haluska，SN Gettinger报告。
- 在细胞培养，IC50 AP26113为CD74-ROS1是，18纳米，堪与EML4-ALK，17纳米;表皮生长因子受体T790M，282纳米和694纳米。从这些数字推断，AP26113具有更好的机会成为有效的非小细胞肺癌ROS1，比EGFR突变T790M非小细胞肺癌
- 在2013年，5同伙设计AP26113包括队列4 - “其他癌症与AP26113的目标，如ALK，ROS1和其他”。但后来我想，他们放弃了队列，以及表皮生长因子受体T790M队列（＃3）。
https://clinicaltrials.gov/ct2/s ... =ap26113&rank=1
目前AP26113阶段2只有2同伙，都ALK +非小细胞肺癌，唯一的区别是量，1组是90毫克，队列2为180毫克。
我在第1阶段，并正在采取240毫克医生的批准后（异常）。
也许，让我问你，当你说ROS1阳性患者在中国试图AP26113 ，几乎没有人取得过成功。有多少病人？你有多大的样本规模？ |
|
IP卡
狗仔卡
发表于 2015-7-8 11:37:24
显身卡
感谢主，能感受到您的乐观和幽默！